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Abstract Headache is one of the commonest conditions
to affect children and adolescents in industrialized coun-
tries. Effective pharmacological treatments without side
effects are still lacking. Ginkgolide B, an herbal constituent
extract from ginkgo biloba tree leaves, is a natural anti-
platelet activating factor (PAF). PAF is a potent proin-
ﬂammatory and nociceptive agent released during the
inﬂammation process. Therefore, Ginkgolide B can be
considered a promising non-pharmacological tool for
treatment of migraine with and without aura. We propose
to determine the efﬁcacy of Ginkgolide B as preventive
treatment in a group of young patients suffering from
migraine without aura. A small sample of 24 young
patients suffering from migraine without aura entered the
open-label prospective trial. Migraine without aura was
diagnosed according to International Headache Society
criteria. The treatment was well tolerated and the compli-
ance was good. These preliminary data show that Gink-
golide B seems to be effective as preventive treatment in
reducing migraine attack frequency and in attenuating the
use of symptomatic medication in our small series of
children with primary headache.
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Introduction
Headache is one of the commonest conditions to affect
children and adolescents in industrialized countries. Stud-
ies indicate a prevalence of 8 to 60% [1]. In over 40% of
migraineurs the condition begins before 18 years of age
[1]. Recurrent headaches turn out common in children and
adolescents, and they often considerably reduce quality of
life [2], with a negative impact on school and social
activity [3]. Primarily, treatment of migraine in young age
consists of avoidance of triggers, and regular habits of life
(sleep, meals, computer&TV, and sports). Very often par-
ents prefer non-pharmacological treatment for their chil-
dren, limiting the assumption of symptomatic medication
when absolutely necessary for migraine attack. Treatment
for the various forms of childhood headache has been the
subject of wide debate in recent years. For migraine and
tension-type headache, the same preventive drugs as used
in adults are widely prescribed for children, but at reduced
dosage. Effective pharmacological treatments without side
effects are still lacking. Most of current non-pharmaco-
logical treatment modalities have been employed (either
medication or behavioral) often with unsatisfactory results.
Among non-pharmacological approach until now, magne-
sium has been successfully used for headache treatment in
young patients, in particular for tension-type headache [4].
Few pharmacological studies have included treatment
comparisons, one of the most recent experience has been
performed by our group [5]. One of the most urgent and
important problem with this kind of patients is to have
therapeutic possibilities without side effects, which are
common with pharmacological treatments.
Ginkgolide B, an herbal constituent extract from ginko
biloba tree leaves, is a natural antiplatelet activating factor
(PAF). PAF is a potent proinﬂammatory and nociceptive
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tion, Ginkgolide B modulates the action of glutamate acid,
the main excitatory neurotransmitter of CNS. It is known
that abnormal levels of glutamate may cause spreading
depression and migraine aura in the susceptible individuals
and the PAF, released from platelets and leukocytes during
the ﬁrst phase of migraine without aura attacks, sensitizes
the trigeminal-vascular endings and induces pain. There-
fore, Ginkgolide B can be considered a promising non-
pharmacological tool for treatment of migraine with and
without aura [6].
On the basis of this evidence, we propose to determine
the efﬁcacy of Ginkgolide B as preventive treatment in a
group of young patients suffering from migraine without
aura.
Patients and methods
A small sample of 24 young patients suffering from
migraine without aura entered the open-label prospective
trial. Migraine without aura was diagnosed according to
International Headache Society (IHS) criteria [7]. All
patients were recruited at the Headache Center of C. Besta
Neurological Institute. Inclusion criteria were: age between
8 and 18 years, initial onset of migraine at least one year
before, and at least four migraine attacks (4 days/headache/
month) each of the 3 months prior to the screening.
Exclusion criteria were: neurological or psychiatric dis-
eases, neuroleptic or antidepressive medication within
6 months before screening, intake of prophylactic medi-
cation for migraine in the 6 months before screening, and
medication overuse.
They were treated with a combination of Ginkgolide B
80 mg, coenzyme Q10 20 mg, vitamin B2 1.6 mg, and
magnesium 300 mg in oral administration twice per day, in
the morning and in the evening, with meals, for 3 months.
Number, duration, and severity of migraine attacks and
analgesic intake were assessed in a diary card 1 month
before the starting of the trial and during the treatment
period. After 3 months, all patients were checked with
their daily card for number, duration, severity headache
episodes, and analgesic consumption. Follow-up sessions
were planned for 3, and 6 months after screening visit.
Results
This study includes a total of 24 patients (12 females and
12 males; mean age was 13.4 ± 2.1). Mean duration of
illness was 3.7 ± 2.6 years. The mean number of days of
headache per month was 9.3 ± 7.6; the mean number
of medications per month was 5.7 ± 4.4.
As much as 14 patients (58.3%) have already achieved
the 6-month follow-up. The number of monthly migraine
attacks was substantially reduced after 3 months of treat-
ment with Ginkgolide B in relation to prestudy baseline.
Starting with a mean baseline of 7.4 ± 5 attacks, clinical
improvement was signiﬁcant: the mean number of days of
headache per month decreased to 2.2 ± 2.8 (p = 0.0015),
with a decrease of number of analgesics used for the
attacks from 5.9 ± 5.3 to 1.5 ± 2.2 (p = 0.013).
The treatment was well tolerated and the compliance
was good: patients (and parents too) reported substantial
improvement of their migraine compared to the situation
prior to the study. None of the patients reported worsening
of migraine.
Conclusion
The authors are aware that the uncontrolled open-label
design of this study and the small sample of patients do not
allow drawing deﬁnite conclusions regarding efﬁcacy and
tolerability of this kind of treatment. These preliminary
data show that Ginkgolide B seems to be effective as
preventive treatment in reducing migraine attack frequency
and in attenuating the use of symptomatic medication in
our small series of children with primary headache.
How Ginkgolide B improved migraine in young age is
still unclear; to date the mechanism of action of Ginkgolide
B on the CNS is not completely understood. It is believed
that the main therapeutical effect may be due to the mod-
ulation and/or reducing the excitatory effect of glutamate in
the CNS, and glutamate is involved in spreading depression
[8]. Another effect of Ginkgolide B is to hinder the
pathological action of PAF, that during some physiopath-
ological circumstances in CNS, sensitizes the trigeminal-
vascular endings and induces pain [9].
Although the results are very preliminary, this treatment
could be a good option for patients suffering from migraine
without aura in particular for young patients, where ther-
apies without side effects are needed.
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